Improved repeatability of nasal potential difference with a larger surface catheter

Journal of Cystic Fibrosis

Volumn 14, Issue 3, 2015, Pages 317-323

  Vermeulen, François ^a   Proesmans, Marijke ^a   Boon, Mieke ^a   De Boeck, Kris ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Biomarker; CFTR function; Surrogate endpoint

Indexed keywords

CHLORIDE; IVACAFTOR; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; BIOPOTENTIAL AMPLIFIER; CATHETER; CHLORIDE TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTRODE; HUMAN; ION TRANSPORT; MEASUREMENT REPEATABILITY; NASAL CATHETER; NASAL POTENTIAL DIFFERENCE; RESPIRATORY TRACT PARAMETERS; SODIUM TRANSPORT; SURFACE AREA; THERAPY EFFECT; TURBINATE; CYSTIC FIBROSIS; DEVICES; EQUIPMENT DESIGN; MEMBRANE POTENTIAL; METABOLISM; MIDDLE AGED; NOSE MUCOSA; PATHOPHYSIOLOGY; RESPIRATORY TRACT EXAMINATION;

CATHETERS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIAGNOSTIC TECHNIQUES, RESPIRATORY SYSTEM; EQUIPMENT DESIGN; HUMANS; ION TRANSPORT; MEMBRANE POTENTIALS; MIDDLE AGED; NASAL MUCOSA;

EID: 84937522740     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.08.006     Document Type: Article

References (22)

1. Accurso F.J., Rowe S.M., Clancy J.P., Boyle M.P., Dunitz J.M., Durie P.R., et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010, 363:1991-2003.
2. Ramsey B.W., Davies J., McElvaney N.G., Tullis E., Bell S.C., Drevinek P., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011, 365:1663-1672.
3. Van Goor F., Hadida S., Grootenhuis P.D., Burton B., Stack J.H., Straley K.S., et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci U S A 2011, 108:18843-18848.
4. Welch E.M., Barton E.R., Zhuo J., Tomizawa Y., Friesen W.J., Trifillis P., et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007, 447:87-91.
5. Rowe S.M., Accurso F., Clancy J.P. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc 2007, 4:387-398.
6. Knowles M.R., Paradiso A.M., Boucher R.C. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995, 6:445-455.
7. Wilschanski M., Yahav Y., Yaacov Y., Blau H., Bentur L., Rivlin J., et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003, 349:1433-1441.
8. Sermet-Gaudelus I., Boeck K.D., Casimir G.J., Vermeulen F., Leal T., Mogenet A., et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010, 182:1262-1272.
9. Yaakov Y., Kerem E., Yahav Y., Rivlin J., Blau H., Bentur L., et al. Reproducibility of nasal potential difference measurements in cystic fibrosis. Chest 2007, 132:1219-1226.
10. Middleton P.G., House H.H. Measurement of airway ion transport assists the diagnosis of cystic fibrosis. Pediatr Pulmonol 2010, 45:789-795.
11. Vermeulen F., Proesmans M., Feyaerts N., De Boeck K. Nasal potential measurements on the nasal floor and under the inferior turbinate: does it matter?. Pediatr Pulmonol 2011, 46:145-152.
12. Leonard A., Lebecque P., Dingemanse J., Leal T. A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference. J Cyst Fibros 2012, 11:231-236.
13. European Cystic Fibrosis Society Diagnostic Network Working Group and Clinical Trials Network Nasal potential difference measurement for diagnosis and clinical trials in cystic fibrosis 2013, [Last accessed 21 Apr 2013].
14. Rowe S.M., Clancy J.P., Wilschanski M. Nasal potential difference measurements to assess CFTR ion channel activity. Methods Mol Biol 2011, 741:69-86.
15. Rowe S.M., Liu B., Hill A., Hathorne H., Cohen M., Beamer J.R., et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation. PLoS One 2013, 8:e66955.
16. Bronsveld I., Vermeulen F., Sands D., Leal T., Leonard A., Melotti P., et al. Influence of perfusate temperature on nasal potential difference. Eur Respir J 2013, 42:389-393.
17. Bland J.M., Altman D.G. Measuring agreement in method comparison studies. Stat Methods Med Res 1999, 8:135-160.
18. Knowles M.R., Carson J.L., Collier A.M., Gatzy J.T., Boucher R.C. Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo. Am Rev Respir Dis 1981, 124:484-490.
19. Middleton P.G., Geddes D.M., Alton E.W. Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur Respir J 1994, 7:2050-2056.
20. Standaert T.A., Boitano L., Emerson J., Milgram L.J., Konstan M.W., Hunter J., et al. Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol 2004, 37:385-392.
21. Solomon G.M., Konstan M.W., Wilschanski M., Billings J., Sermet-Gaudelus I., Accurso F., et al. An international randomized multicenter comparison of nasal potential difference techniques. Chest 2010, 138:919-928.
22. Clancy J.P., Rowe S.M., Bebok Z., Aitken M.L., Gibson R., Zeitlin P., et al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol 2007, 37:57-66.